Thank you, Mr. Chairman.
I'd like to start my comments by saying that unfortunately Paul Glover, who is responsible for managing the existing substances program, is not here this morning. The area I'm responsible for deals more with new substances, and the risk management approaches that we take for both new and existing substances differ somewhat.
It's hard to comment on how we would manage anything that would end up on the schedule 1 list without the benefit of a very thorough risk assessment that identifies for us what the risk is that needs to be managed or controlled. Once we've managed to do that, then the appropriate risk management mechanism is put in place. That could be regulation. It could be voluntary. It could be just an issue of public awareness and restricted use of a particular substance. It's very difficult to comment on what the mechanism would be without the full benefit of the very thorough risk analysis.